Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

Project description

Real-time dose monitoring for cancer patients

Proton radiotherapy is a powerful cancer treatment, but its potential is limited by the fact that there is no way to check in real time if the radiation dose is hitting the right spot accurately. The EIC-funded NOVO project aims to change this by developing the first proof-of-concept technology for checking radiation dose in real time, adaptable to any proton radiotherapy treatment. This technology will enable real-time, dose-guided adaptive therapy, allowing personalised cancer treatment that improves outcomes and reduces side effects. It will combine cutting-edge organic scintillator technology, AI-enhanced image reconstruction, tumour tracking and intelligent automation to measure radiation doses in real time. The NOVO consortium will include experts across disciplines, such as physicists, chemists, mathematicians, computer scientists, oncologists and biologists.

Objective

The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the first proof-of-concept of an RDV technology adaptable to any PT treatment and bring the concept to TRL 4 by also considering integration into the PT clinical workflow. The RDV technology will be pivotal for enabling the next generation of adaptive PT therapy, i.e. dose-guided real-time adaptive therapy. Real-time measurement of the dose to targeted and non-targeted tissues will be the key to truly empower patient-centered, personalized cancer treatment, important to improve curation and quality-of-life post-treatment. As a high-risk/high-gain project, NOVO aims at a first-of-its-kind RDV technology through the unique synergy between (1) cutting-edge, inexpensive organic scintillator technology that can detect secondary radiation during treatment for non-invasive measurements, (2) novel and fast image reconstruction, artificial intelligence (AI)-accelerated models and AI-enhanced image reconstruction to allow simultaneous detection of multiple radiation species and tissue compositional analysis, (3) tumor-tracking and imaging of tissue radio-sensitivity based on oxygen levels, (4) intelligent automation of decision-making schemes for real-time dose-guided adaptive therapy. The project will essentially open a new era in PT that enables curing more cancer patients and reducing toxicity from treatment. The NOVO consortium covers the entire value chain of RDV development (technology providers, theory and modelling, technology integration and PT clinics) and optimally engages nuclear, medical, and high-energy physicists, chemists, mathematicians, computer scientists, oncologists, biologists, as well as European PT centers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-PATHFINDEROPEN-01

See all projects funded under this call

Coordinator

HOGSKULEN PA VESTLANDET
Net EU contribution
€ 661 598,75
Address
INNDALSVEIEN 28
5020 Bergen
Norway
Region
Norge Vestlandet Vestland
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 661 598,75

Participants (7)

Partners (1)